Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Language
Year
  • 1
    Language: English
    In: Future oncology (London, England), September 2018, Vol.14(22), pp.2293-2302
    Description: Systemic treatments for advanced hepatocellular carcinoma (HCC) are evolving rapidly and several multi-targeted tyrosine kinase inhibitors have demonstrated a survival advantage over best supportive care. Despite these treatment advances, the majority of HCC patients will progress on tyrosine kinase inhibitor therapy. Preclinical data indicate that interference with immune checkpoint molecules results in HCC growth suppression. Several clinical trials applying monoclonal antibodies to immune checkpoint molecules have demonstrated durable antitumor activity in advanced HCC patients. As such, pivotal clinical trials are now in progress to assess if these agents will alter the natural history of the disease and further extend the overall survival of advanced HCC patients. This manuscript will review the current status of immune checkpoint blockade in patients with advanced HCC.
    Keywords: Ctla-4 ; PD-1 ; Hepatocellular Carcinoma ; Immune Checkpoint Inhibitors ; Immunotherapy ; Carcinoma, Hepatocellular -- Therapy ; Liver Neoplasms -- Therapy ; Molecular Targeted Therapy -- Methods
    ISSN: 14796694
    E-ISSN: 1744-8301
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: The New England Journal of Medicine, 2012, Vol.366(9), pp.866-868
    Description: Patients with melanoma who have received ipilimumab appear to be at an increased risk for a drug-hypersensitivity rash when treated with vemurafenib. To the Editor: Ipilimumab1,2 and vemurafenib3 each improve the overall survival of patients with metastatic melanoma. Ipilimumab was approved by the Food and Drug Administration in March 2011; vemurafenib was approved 5 months later. As a result, patients with disease progression during treatment with ipilimumab are being switched to treatment with vemurafenib. We treated 13 patients with the BRAF V600E mutation with ipilimumab, which was later replaced by vemurafenib (Table 1; doses of ipilimumab are given in milligrams per kilogram of body weight), and a pruritic, grade 3 (severe), maculopapular rash developed in 4 of these patients within 6 . . .
    Keywords: Patients ; Skin ; Hypersensitivity ; FDA Approval ; Drug Dosages ; Melanoma ; Food & Drug Administration–FDA;
    ISSN: 0028-4793
    E-ISSN: 1533-4406
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Cancer, Feb 1, 2016, Vol.122(3), p.367(11)
    Keywords: Hepatocellular Carcinoma – Care and Treatment ; Hepatocellular Carcinoma – Diagnosis ; Immunotherapy – Usage ; Sorafenib – Dosage and Administration ; Clinical Trials – Usage
    ISSN: 0008-543X
    Source: Cengage Learning, Inc.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: The New England Journal of Medicine, 2012, Vol.367(24), pp.2316-2321
    Description: Vemurafenib, a selective RAF inhibitor, extends survival among patients with BRAF V600E–mutant melanoma. Vemurafenib inhibits ERK signaling in BRAF V600E–mutant cells but activates ERK signaling in BRAF wild-type cells. This paradoxical activation of ERK signaling is the mechanistic basis for the development of RAS-mutant squamous-cell skin cancers in patients treated with RAF inhibitors. We report the accelerated growth of a previously unsuspected RAS-mutant leukemia in a patient with melanoma who was receiving vemurafenib. Exposure to vemurafenib induced hyperactivation of ERK signaling and proliferation of the leukemic cell population, an effect that was reversed on drug withdrawal. A man with undiagnosed chronic myelomonocytic leukemia began treatment with vemurafenib for BRAF-mutant metastatic melanoma. His white-cell count soared and then dropped when the drug was withdrawn. The leukemia cells contained an RAS mutation that became more active with RAF inhibition. Approximately 50% of patients with metastatic melanoma harbor a somatic V600E mutation — or, less frequently, a V600K mutation — in the BRAF kinase.1–4 These activating mutations drive increased ERK signaling, promoting the proliferation and survival of melanoma cells.5 Selective RAF inhibitors, such as vemurafenib and dabrafenib, inhibit ERK signaling and arrest growth in tumors with BRAF V600E or BRAF V600K mutations.3,6–8 Treatment with vemurafenib or dabrafenib induces tumor regression in more than half of patients with BRAF V600E–mutant metastatic melanoma. Both drugs also improve the rate of progression-free survival, as compared with dacarbazine.7,9–11 Vemurafenib . . .
    Keywords: Medicine;
    ISSN: 0028-4793
    E-ISSN: 1533-4406
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Cancer Research, 07/01/2017, Vol.77(13 Supplement), pp.CT090-CT090
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer, 15 October 2013, Vol.119(20), pp.3687-3695
    Description: Ipilimumab can induce clinical responses and durable stable disease, with manageable toxicity, in metastatic uveal melanoma. Eastern Cooperative Oncology Group performance status and pretreatment low‐density lipoprotein levels correlate with improved survival in multivariate analysis, and the week‐7 absolute lymphocyte count may represent a biomarker of treatment efficacy.
    Keywords: Uveal Melanoma ; Ipilimumab ; Cytotoxic T‐Lymphocyte—Associated Protein 4 ; Immunotherapy ; Absolute Lymphocyte Count
    ISSN: 0008-543X
    E-ISSN: 1097-0142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
  • 8
    In: Archives in Cancer Research, 2016, Vol.4(3)
    ISSN: Archives in Cancer Research
    E-ISSN: 22546081
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Translational gastroenterology and hepatology, 2018, Vol.3, pp.107
    ISSN: 2415-1289
    ISSN: Translational Gastroenterology and Hepatology
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: Chinese clinical oncology, December 2013, Vol.2(4), pp.37
    Description: The prognosis is poor for patients with advanced hepatocellular carcinoma (HCC). Sorafenib is the only accepted standard of care for advanced disease. The benefits of this agent are modest and the precise mechanism of antitumor activity in HCC is unknown. Since the approval of sorafenib, there has been intense investigation into strategies that block angiogenic pathways. Unfortunately, the results of three randomized phase III trials that compared newer anti-angiogenic treatments to sorafenib failed to demonstrate their superiority or non-inferiority. Thus, there remains a critical need for both continued molecular characterization and aggressive drug development in hepatocellular carcinoma.
    Keywords: Hepatocellular Carcinoma (Hcc) ; Anti-Angiogenic Therapy ; Drug Development ; Hepatocarcinogenesis ; Sorafenib
    ISSN: 23043865
    E-ISSN: 2304-3873
    Source: MEDLINE/PubMed (U.S. National Library of Medicine)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages